TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Tissue Regenix ( (GB:TRX) ) has issued an update.
Tissue Regenix has announced an urgent need to raise capital due to a substantial backlog of creditors and limited cash reserves, following a restatement of revenue numbers for the financial year 2024. The company is in discussions with major shareholders to raise approximately £5 million through a convertible loan note, which is crucial for its continued operation and subject to shareholder approval.
The most recent analyst rating on (GB:TRX) stock is a Hold with a £8.00 price target. To see the full list of analyst forecasts on Tissue Regenix stock, see the GB:TRX Stock Forecast page.
Spark’s Take on GB:TRX Stock
According to Spark, TipRanks’ AI Analyst, GB:TRX is a Neutral.
The overall stock score is primarily influenced by financial performance, which shows some operational improvements but significant challenges remain. Technical analysis indicates bearish momentum, and valuation metrics reflect ongoing financial struggles. The earnings call provided some positive insights, but these were outweighed by revenue declines and regulatory issues.
To see Spark’s full report on GB:TRX stock, click here.
More about Tissue Regenix
Tissue Regenix is a leading medical device company in regenerative medicine, known for its patented decellularisation technology (dCELL®) which creates acellular tissue scaffolds for repairing damaged body structures. The company focuses on applications in sports medicine, foot and ankle injuries, and wound care. In 2017, it acquired CellRight Technologies, a biotech firm specializing in regenerative medicine for surgical procedures across various medical fields.
Average Trading Volume: 470,894
Technical Sentiment Signal: Sell
Current Market Cap: £5.16M
See more data about TRX stock on TipRanks’ Stock Analysis page.